Treatment of human malignant MM415 melanoma cell line in vitro and a MM415 melanoma xenograft mouse model in vivo with cell-penetrating PDE8A-C-Raf complex disruptor peptide agent (PPL-008) leads to reduced phospho-ERK signaling and growth inhibition. This evidence concerns the gene PDE8A and melanoma.